Acumed, a Colson Medical | Marmon | Berkshire Hathaway company, is excited to announce the acquisition of ExsoMed, a provider of innovative solutions for hand surgery.
Colson Medical, LLC announces Hjalmar Pompe van Meerdervoort as President, Acumed, effective June 1. Pompe van Meerdervoort succeeds Sharon Wolfngton, who will transition into a new advisory role for Colson Medical, LLC. After nearly five years at Acumed, Wolfington chose to pursue other professional and personal opportunities.
Acumed is pleased to announce the launch of the Ulna Nail 2 System, created to treat simple, transverse, and short oblique fractures, as well as osteotomies of the ulna.
Acumed is excited to announce the OsteoMed product line will be managed and co-marketed with Acumed’s comprehensive portfolio of industry-first solutions to better serve our customers worldwide.
Acumed is pleased to announce the launch of the Ankle Syndesmosis Repair System with Acu-Sinch Knotless technology. The system was developed by a group of surgeons focused on trauma and the needs of foot and ankle specialists.
Acumed | OsteoMed is pleased to announce the opening of our new logistics center in Madrid, Spain, that will enhance our customer experience in the European Union (EU) by reducing delivery times, mitigating supply chain risks, and accelerating growth.
The Acumed Fibula Nail 2 System is designed to provide an alternate treatment to bone plating by offering a less invasive intramedullary approach to fractures of the fibula.
The Acumed | OsteoMed PFX Choice™ program is designed to help customers choose the right combination of products, customer service, payment, and billing options to meet their unique needs.
Acumed | OsteoMed is proud to be Certified™ by Great Place to Work®. This prestigious award is based entirely on what current employees say about their experience working at Acumed | OsteoMed. This year, 80% of employees said it’s a great place to work – 21 points higher than the average US company.
The combined Acumed | OsteoMed organization will be structured into Business Units whose leaders will be responsible for global sales, marketing, and research and development.
